Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

Sikander AilawadhiSwetha ChallagullaPo-Ya ChuangWesley FurnbackKeri Yang2026-03-222026-03-22202610.1080/17474086.2026.2628534https://doi.org/10.1080/17474086.2026.2628534https://andeanlibrary.org/handle/123456789/79658This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.enMedicineIbrutinibDiscontinuationChronic lymphocytic leukemiaBruton's tyrosine kinaseOncologyInternal medicineTyrosine kinaseHealth careLeukemiaReal-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemiaarticle